Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
BackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591656642150400 |
|---|---|
| author | Zhifeng Gao Huan Deng Bowen Qin Liang Bai Jiangwei Li Jian Zhang |
| author_facet | Zhifeng Gao Huan Deng Bowen Qin Liang Bai Jiangwei Li Jian Zhang |
| author_sort | Zhifeng Gao |
| collection | DOAJ |
| description | BackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe utilized data from the NHANES 2017 to March 2020. Multivariate logistic regression models were employed to control for sociodemographic and metabolic factors to determine the associations between hypertension, MASLD, and fibrosis.ResultsOf the total cohort (N = 5,967) 57.92% had hypertension, 38.8% had MASLD, 25.88% had both MASLD and hypertension. Patients with MASLD were more likely to have hypertension (64.24% vs. 44.80%). There was a significant association between stage I (OR1.70, 95% CI: 1.15–2.53) and stage II hypertension (OR1.98, 95% CI: 1.38–2.85) and an increased risk of SF. After adjusting for multiple confounding factors, stage I (OR1.59, 95% CI: 1.09–2.24) and stage II hypertension (OR1.48, 95% CI: 1.06–2.06) remained significantly associated with the risk of SF. Patients with both MASLD and hypertension had higher rates of SF at 14.83% and AF at 7.47%. After adjusting for sociodemographic factors, those patients still had an 8.02-fold increased risk of SF (OR8.02, 95% CI: 4.47–14.39) and a 15.13-fold increased risk of AF (OR15.13, 95% CI: 7.09–32.3). Further adjustment for metabolic factors, those patients still had a significantly higher risk of SF (OR3.07, 95% CI: 1.83–5.14) and AF (OR4.01, 95% CI: 1.48–10.89).ConclusionMASLD and hypertension are at risk for fibrosis, and the coexistence of the two has a more significant impact on the risk of fibrosis. |
| format | Article |
| id | doaj-art-958ee64ee9fa4850af78c7a8d543cea1 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-958ee64ee9fa4850af78c7a8d543cea12025-01-22T07:14:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.15392831539283Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver diseaseZhifeng Gao0Huan Deng1Bowen Qin2Liang Bai3Jiangwei Li4Jian Zhang5Department of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, ChinaNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaBackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe utilized data from the NHANES 2017 to March 2020. Multivariate logistic regression models were employed to control for sociodemographic and metabolic factors to determine the associations between hypertension, MASLD, and fibrosis.ResultsOf the total cohort (N = 5,967) 57.92% had hypertension, 38.8% had MASLD, 25.88% had both MASLD and hypertension. Patients with MASLD were more likely to have hypertension (64.24% vs. 44.80%). There was a significant association between stage I (OR1.70, 95% CI: 1.15–2.53) and stage II hypertension (OR1.98, 95% CI: 1.38–2.85) and an increased risk of SF. After adjusting for multiple confounding factors, stage I (OR1.59, 95% CI: 1.09–2.24) and stage II hypertension (OR1.48, 95% CI: 1.06–2.06) remained significantly associated with the risk of SF. Patients with both MASLD and hypertension had higher rates of SF at 14.83% and AF at 7.47%. After adjusting for sociodemographic factors, those patients still had an 8.02-fold increased risk of SF (OR8.02, 95% CI: 4.47–14.39) and a 15.13-fold increased risk of AF (OR15.13, 95% CI: 7.09–32.3). Further adjustment for metabolic factors, those patients still had a significantly higher risk of SF (OR3.07, 95% CI: 1.83–5.14) and AF (OR4.01, 95% CI: 1.48–10.89).ConclusionMASLD and hypertension are at risk for fibrosis, and the coexistence of the two has a more significant impact on the risk of fibrosis.https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/fullhypertensionmetabolic dysfunction-associated steatotic liver diseasesignificant fibrosisadvanced fibrosisassociation |
| spellingShingle | Zhifeng Gao Huan Deng Bowen Qin Liang Bai Jiangwei Li Jian Zhang Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease Frontiers in Medicine hypertension metabolic dysfunction-associated steatotic liver disease significant fibrosis advanced fibrosis association |
| title | Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease |
| title_full | Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease |
| title_fullStr | Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease |
| title_full_unstemmed | Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease |
| title_short | Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease |
| title_sort | impact of hypertension on liver fibrosis in patients with metabolic dysfunction associated fatty liver disease |
| topic | hypertension metabolic dysfunction-associated steatotic liver disease significant fibrosis advanced fibrosis association |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/full |
| work_keys_str_mv | AT zhifenggao impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease AT huandeng impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease AT bowenqin impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease AT liangbai impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease AT jiangweili impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease AT jianzhang impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease |